Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab

Elneil, Sohier; Lalezari, Jacob; Pourhassan, Nader

doi:10.1016/j.jtauto.2021.100097

Cited by 6 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 98 Emapalumab Human IgG1 - IFN-γ - Phase 2/3 (NCT04324021) 99 Leronlimab (PRO 140) Humanized IgG4κ Mouse CCR5 - Phase 2/3 (NCT04343651, etc.) 100 Complement Ravulizumab Humanized IgG2 Mus musculus C5 - Phase 3/4 (NCT04570397, etc.) 101 Eculizumab Humanized IgG2/4κ Mouse C5 - Phase 2/3 (NCT04288713, etc.)…”

Section: Sars-cov-2 and Conventional Igg Mabsmentioning

confidence: 99%

Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?

Zhang

Sun

2022

mAbs

View full text Add to dashboard Cite

Early humoral immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are dominated by IgM and IgA antibodies, which greatly contribute to virus neutralization at mucosal sites. Given the essential roles of IgM and IgA in the control and elimination of SARS-CoV-2 infection, the mucosal immunity could be exploited for therapeutic and prophylactic purposes. However, almost all neutralizing antibodies that are authorized for emergency use and under clinical development are IgG antibodies, and no vaccine has been developed to boost mucosal immunity for SARS-CoV-2 infection. In addition to IgM and IgA, bispecific antibodies (bsAbs) combine specificities of two antibodies in one molecule, representing an important alternative to monoclonal antibody cocktails. Here, we summarize the latest advances in studies on IgM, IgA and bsAbs against SARS-CoV-2. The current challenges and future directions in vaccine design and antibody-based therapeutics are also discussed.

show abstract

Section: Sars-cov-2 and Conventional Igg Mabsmentioning

confidence: 99%

Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?

Zhang

Sun

2022

mAbs

View full text Add to dashboard Cite

show abstract

Variant-genetic and transcript-expression analysis showed a role for the chemokine-receptor CCR5 in COVID-19 severity

Cuesta‐Llavona

Gómez

Albaiceta

et al. 2021

International Immunopharmacology

View full text Add to dashboard Cite

The chemokine receptor CCR5 has been implicated in COVID-19. CCR5 and its ligands are overexpressed in patients. The pharmacological targeting of CCR5 would improve the COVID-19 severity. We sought to investigate the role of the CCR5-Δ32 variant (rs333) in COVID-19. The CCR5 -Δ32 was genotyped in 801 patients (353 in the intensive care unit, ICU) and 660 healthy controls, and the deletion was significantly less frequent in hospitalysed COVID-19 than in healthy controls (p=0.01, OR=0.66 , 95%CI=0.49-0.88). Of note, we did not find homozygotes among the patients, compared to 1% of the controls. The CCR5 transcript was measured in leukocytes from 85 patients and 40 controls. We found a significantly higher expression of the CCR5 transcript among the patients, with significant difference when comparing the non-deletion carriers (controls=35; patients=n=81; p=0.01). ICU-patients showed non-significantly higher expression than no-ICU cases. Our study points to CCR5 as a genetic marker for COVID-19. The pharmacological targeting of CCR5 should be a promising treatment for COVID-19.

show abstract

Expert guidance on the management and challenges of long-COVID syndrome: a systematic review

Ora

Calzetta

Frugoni

et al. 2023

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab

Cited by 6 publications

References 18 publications

Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?

Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?

Variant-genetic and transcript-expression analysis showed a role for the chemokine-receptor CCR5 in COVID-19 severity

Expert guidance on the management and challenges of long-COVID syndrome: a systematic review

Contact Info

Product

Resources

About